Idorsia Ltd
A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment
- Conditions
- Hepatic Impairment
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2020-07-02
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03713242
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland
A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03688555
- Locations
- 🇧🇪
University Hospital Ghent, Gent, Belgium
🇩🇪Charité Research Organisation GmbH, Berlin, Germany
Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
- Conditions
- Insomnia Disorder
- Interventions
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 804
- Registration Number
- NCT03679884
- Locations
- 🇺🇸
Noble Clinical Research, Tucson, Arizona, United States
🇺🇸Preferred Research Partners, Inc, Little Rock, Arkansas, United States
🇺🇸Core Healthcare Group, Cerritos, California, United States
A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03657446
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users
- Conditions
- Healthy Recreational Drug Users
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT03657355
- Locations
- 🇨🇦
Altasciences Company Inc., Montreal, Canada
🇺🇸Altasciences Clinical Kansas, Inc. (former Vince and Associates Clinical Research, Inc.), Overland Park, Kansas, United States
A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT03646864
- Locations
- 🇩🇪
framol-med GmbH, Lungenpraxis, Rheinau, Germany
🇩🇪Advanced Sleep Research, Berlin, Germany
🇩🇪ZMS, Warendorf, Germany
A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT03609775
- Locations
- 🇳🇱
Centre For Human Drug Research, Leiden, Netherlands
A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03596294
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03593278
- Locations
- 🇩🇪
Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany
🇩🇪Universitäts-Herzzentrum Bad Krozingen, Bad Krozingen, Germany
🇩🇪Universitäts-Herzzentrum Freiburg, Freiburg, Germany
A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03586570
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States